Skip to main content
Quest Diagnostics Home
Talk to an expert
Call
Menu

Primary care is the first line of defense for patients experiencing symptoms of autoimmune disorders

Primary care providers (PCPs) know firsthand that recognizing autoimmune disease can be challenging due to vague, variable, and overlapping symptoms. That makes it even more important for you to get comprehensive autoimmune insights for your patients sooner, so you can make sure the next step on their healthcare journey is in the right direction. 

Connect directly with a dedicated representative.

 

 

Consult with clinical experts about a complex patient case or results interpretation.

 
Confidently approach autoimmune screening and results interpretation with our quick reference guide

Employ reliable testing solutions for accurate results.

 

 

Why it’s crucial to get earlier insights through comprehensive autoimmune screening

 Delayed autoimmune diagnosis and treatment can result in permanent joint and organ damage and lower the chance of remission.1 It’s more important than ever for PCPs to use comprehensive autoimmune screening solutions due to: 

Non-specificity with ANA screening 

Antinuclear antibody (ANA) screening alone is not disease-specific, meaning it requires more follow-up visits and testing.

Long wait time for rheumatologists 

6 weeks is the recommended time to visit a rheumatologist after symptom onset1 but current wait time for new patients is up to 6 months2

Recent increase of at-risk populations 

>100 million confirmed US COVID-19 cases,3 with new data suggesting this population has a significantly higher risk of autoimmune disease4

 

 

You are critical to helping improve patient outcomes.

 Learn more about healthcare trends that are shaping the PCP role in autoimmune care.  

Get the resource

Autoimmune symptoms may be complex, but getting answers doesn’t have to be.

1  test code. 1 blood draw. 1 confident referral. More insights. Quest’s comprehensive screening panels deliver ANA results plus disease-specific insights that increase specificity, so you can enable a more qualified referral and a faster path to diagnosis. 
Download the free guide

Help your patients get the care they need sooner

Reliable results

- Greater sensetivity with ANA gold-standard indirect fluorescent antibody (IFA) methodology.

- Improved consistancy through automation.

Accessible testing

- Extensive network of 2,100 Patient Service Centers.

- In-network with most health plans. 

Actionable insights

- Identifies multiple ANA patterns and disease-specific autoantibodies.

- Expansive approach supports more informed refferrals.

Easy, simplified experience

- One blood draw reduces need for follow-up visits and tests.

- Access to clinical consults and account support.

ANAlyzer - The analytic approach

ANA, IFA, with Reflex Titer/Pattern, Systemic Autoimmune Panel 1

Fixed panel of 20+ analytes that gives a full-picture view (whether ANA is positive or negative), to support differential diagnosis, especially for patients with more than 1 autoimmune condition
View test details
Hereditary oncology spotlight

Cascade - The reflexive approach

ANA, IFA, Cascade and Rheumatoid Arthritis Panel 2, with Reflexes

Automatic reflex panel that screens for the 8 most common autoimmune diseases, where positive ANA results reflex to a tiered cascade of specific antibodies.
View test details
Provider walking a patient through results

Your Quest expert is only a phone call away

Let’s discuss some of the key challenges your lab is facing and how we can work together to find the right solution for your diagnostic needs.

684

* indicates required

 

 

1. Niemantsverdriet E, Dougados M, Combe B, van der Helm-van Mil AHM. Referring early arthritis patients within 6 weeks versus 12 weeks after symptoms onset; an observational cohort study. Lancet Rheumatol. 2020;2(6):e332-e338. doi:10.1016/S2665- 9913(20)30061-8

2. American College of Rheumatology Responds to the Senate Health, Education, Pension, & Labor Committee Published March 20, 2023. Accessed July 18, 2023. h#ps://assets.contentstack.io/v3/ass ets/bltee37abb6b278ab2c/bl99244a 31c1fd18fe/acr-help-workforce-rfiresponse.pdf

3. WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization. Updated July 12, 2023. Accessed July 18, 2023. h#ps://covid19.who.int/region/amro /country/us

4. Chang R, Yen-Ting Chen T, Wang SI, Hung YM, Chen HY, Wei CCJ. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. eClinicalMedicine. 2023;56:101783. doi:10.1016/j.eclinm.2022.101783

Our company

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.